JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by He, S.
Right arrow Articles by Walls, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, S.
Right arrow Articles by Walls, A. F.

Vol. 291, Issue 2, 517-523, November 1999

Inhibitors of Chymase as Mast Cell-Stabilizing Agents: Contribution of Chymase in the Activation of Human Mast Cells1

Shaoheng He, Marianna D. A. Gaça, Alan R. McEuen and Andrew F. Walls

Immunopharmacology Group, University of Southampton, Southampton General Hospital, Southampton, United Kingdom

There has long been evidence that inhibitors of chymotryptic proteinases can inhibit the degranulation of rodent mast cells, but their actions on human mast cells and the contribution of mast cell chymase itself have received little attention. We investigated the ability of the selective chymase inhibitor Z-Ile-Glu-Pro-Phe-CO2Me and other proteinase inhibitors to inhibit chymase and cathepsin G activity, and we examined their potential to modulate the responsiveness of mast cells dispersed from human skin, lung, and tonsil tissues. IgE-dependent histamine release from skin mast cells was inhibited by up to about 80% after preincubation with Z-Ile-Glu-Pro-Phe- CO2Me (up to 0.1 µM), 70% with chymostatin (17 µM), and 60% with soybean trypsin inhibitor (0.5 µM). The mast cell-stabilizing properties of chymase inhibitors appeared to be greater for skin mast cells than for those from lung, whereas tonsil mast cells were relatively unresponsive. There were marked differences in the time course of responses to inhibitors, and the effect was dependent on the stimulus, with calcium ionophore-induced histamine release being unaffected. Incubation of dispersed skin, lung, or tonsil cells for up to 45 min with purified chymase failed to induce histamine release, although preincubation of cells with chymase was able to suppress IgE-dependent activation. Chymase could thus contribute to mast cell degranulation and after secretion could provide a feedback mechanism to limit this process. Nevertheless, inhibitors of chymase can be potent mast cell stabilizers, particularly in the skin.


0022-3565/99/2912-0517$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
S. S. Palaniyandi, Y. Nagai, K. Watanabe, M. Ma, P. T. Veeraveedu, P. Prakash, F. A. Kamal, Y. Abe, K. Yamaguchi, H. Tachikawa, et al.
Chymase Inhibition Reduces the Progression to Heart Failure After Autoimmune Myocarditis in Rats
Experimental Biology and Medicine, October 1, 2007; 232(9): 1213 - 1221.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. J. Wolters, C. T. N. Pham, D. J. Muilenburg, T. J. Ley, and G. H. Caughey
Dipeptidyl Peptidase I Is Essential for Activation of Mast Cell Chymases, but Not Tryptases, in Mice
J. Biol. Chem., May 18, 2001; 276(21): 18551 - 18556.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.